15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)

November 14, 2026 updated by: Jun Zhang, Xiamen University

A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangxi
      • Liuzhou, Guangxi, China, 545007
        • Liuzhou Center for Disease Control and Prevention
        • Contact:
    • Hebei
      • Fengning, Hebei, China, 068350
        • Fengning Hospital of Traditional Chinese Medicine
        • Contact:
    • Henan
      • Qingpingjie, Henan, China, 452370
        • Xinmi Maternal and Child Health Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Description

Inclusion Criteria:

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given informed consent and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Vaccine group

Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Control group

Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Time Frame: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Time Frame: At months 156 and 180 after the first dose in the original trial

Infection with the same HPV type must persist for at least 6 months

At months 156 and 180 after the first dose in the original trial

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Time Frame: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
Time Frame: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Time Frame: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
Time Frame: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
Time Frame: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Time Frame: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Time Frame: At months 156 and 180 after the first dose in the original trial

Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Time Frame: At months 156 and 180 after the first dose in the original trial

Serum antibody titers against HPV-16 and HPV-18

At months 156 and 180 after the first dose in the original trial

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
incident HPV-16 and/or HPV-18 infection
Time Frame: At months 156 and 180 after the first dose in the original trial

Newly detected HPV-16 and/or HPV-18 DNA positivity

At months 156 and 180 after the first dose in the original trial

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Jun Zhang, Xiamen University
  • Principal Investigator: Ting Wu, Xiamen University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

November 14, 2026

First Submitted That Met QC Criteria

November 14, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HPV-PRO-003-4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.